0001209191-18-023744.txt : 20180404 0001209191-18-023744.hdr.sgml : 20180404 20180404165658 ACCESSION NUMBER: 0001209191-18-023744 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180402 FILED AS OF DATE: 20180404 DATE AS OF CHANGE: 20180404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LITALIEN JAMES J CENTRAL INDEX KEY: 0001182613 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37693 FILM NUMBER: 18737937 MAIL ADDRESS: STREET 1: C/O SOMAXON PHARMACEUTICALS, INC. STREET 2: 3721 VALLEY CENTRE DRIVE, SUITE 500 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AveXis, Inc. CENTRAL INDEX KEY: 0001652923 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 901038273 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2275 HALF DAY ROAD STREET 2: SUITE 160 CITY: BANNOCKBURN STATE: IL ZIP: 60015 BUSINESS PHONE: 972-725-7797 MAIL ADDRESS: STREET 1: 2275 HALF DAY ROAD STREET 2: SUITE 160 CITY: BANNOCKBURN STATE: IL ZIP: 60015 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-04-02 0 0001652923 AveXis, Inc. AVXS 0001182613 LITALIEN JAMES J C/O AVEXIS, INC. 2275 HALF DAY ROAD, SUITE 200 BANNOCKBURN IL 60015 0 1 0 0 SrVP/Chief Reg&Quality Officer Common Stock 2018-04-02 4 M 0 5000 18.17 A 8800 D Common Stock 2018-04-02 4 S 0 1170 117.10 D 7630 D Common Stock 2018-04-02 4 S 0 569 118.41 D 7061 D Common Stock 2018-04-02 4 S 0 1297 119.43 D 5764 D Common Stock 2018-04-02 4 S 0 1052 120.11 D 4712 D Common Stock 2018-04-02 4 S 0 757 122.14 D 3955 D Common Stock 2018-04-02 4 S 0 155 123.32 D 3800 D Employee Stock Option (Right to Buy) 18.17 2018-04-02 4 M 0 5000 0.00 D 2025-08-11 Common Stock 5000 141800 D These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on September 13, 2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.90 to $117.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.90 to $118.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.94 to $119.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.94 to $120.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.95 to $122.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.97 to $123.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4. 37,950 shares vested and became exercisable on July 20, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until July 20, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date. /s/Darren DeStefano, Attorney-in-Fact 2018-04-04